Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
After 10 years as a men's wear brand, the popular athleisure brand recently launched its women's line, redefining standards and championing inclusivity.
According to the 2024 Acorns Money Matters Report, nearly a quarter of Americans are worried they could become homeless – and don’t know how easy it is to save.
Even with inflation slightly higher than the Federal Reserve's 2% goal, still expect the central bank to cut rates three times this year, Cetera's CIO says.
Brian Goodman from Global Matrix Group talks with Dave Briggs about the future of sports betting online and how the popular pastime will evolve. Watch!
For decades, it’s been a trope: you can find a Starbucks on every corner. But proximity is no guarantee of long-term success, even in the coffee industry.
